Research Article

Endogenous Sex Steroids and Risk of Cervical Carcinoma: Results from the EPIC Study

Sabina Rinaldi1, Martyn Plummer1, Carine Biessy1, Xavier Castellsagué2, Kim Overvad3, Susanne Krüger Kjær4, Anne Tjønneland5, Françoise Clavel-Chapelon6, Nathalie Chabbert-Buffet7,6, Sylvie Mesrine8,9, Annekatrin Lukanova9, Rudolf Kaaks10, Cornelia Weikert10, Heiner Boeing9,11, Antonio Trichopoulos12, Dimitrios Trichopoulos12,13, Domenico Palli14, Claudia Agnoli15, Rosario Tumino15, Paolo Vineis16,17, Salvatore Panico18, Bas Bueno-de-Mesquita19,20, Henk J. van Kranen19, Kjellberg21, Joakim Dillner21, Jonas Manjer22, Salma Butt23, Kay-Tee Khaw23, Nicholas Wareham23, Antonia Trichopoulou9,10, Pagona Lagiou9,11,12, Dimitrios Trichopoulos11,12, Domenico Palli13, Claudia Agnoli14, Petra HM Peeters15,22, Kjersti Bakken22, Eliv Lund23, Inger Torhild Gram23, Laudina Rodriguez23, F Xavier Bosch24, Maria-José Sánchez25,26, Miren Dorronsoro27, Carmen Navarro28,29, Aurelio Barricarte Gurrea28,30, Lennart Kjellberg21, Joakim Dilnèr21, Jonas Manjer22, Salma Butt23, Kay-Tee Khaw23, Nicholas Wareham23, Naomi E. Allen26, Ruth Travis26, Isabelle Romieu1, Pietro Ferrari1, Elio Riboli16, and Silvia Franceschi1

Abstract

Background: Epidemiologic data and animal models suggest that, despite the predominant role of human papillomavirus infection, sex steroid hormones are also involved in the etiology of invasive cervical carcinoma (ICC).

Methods: Ninety-nine ICC cases, 121 cervical intraepithelial neoplasia grade 3 (CIN3) cases and 2 control women matched with each case for center, age, menopausal status and blood collection–related variables, were identified in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Circulating levels of testosterone (T) and estradiol (E2); dehydroepiandrosterone sulfate (DHEAS); progesterone (premenopausal women); and sex hormone–binding globulin (SHBG) were measured using immunoassays. Levels of free (f) T and E2 were calculated from absolute concentrations of T, E2, and SHBG. Odds ratios (ORs) and 95% confidence intervals (CI) were computed using regularized conditional logistic regression.

Results: Among premenopausal women, associations with ICC were observed for fT (OR for highest vs. lowest tertile = 5.16, 95% CI, 1.50–20.1). SHBG level was associated with a significant downward trend in ICC risk. T, E2, fE2, and DHEAS showed nonsignificant positive association with ICC. Progesterone was uninformative. Among postmenopausal women, associations with ICC were found for T (OR = 3.14; 95% CI, 1.21–9.37), whereas E2 and fT showed nonsignificant positive association. SHBG level was unrelated to ICC risk in postmenopausal women. No associations between any hormone and CIN3 were detected in either pre- or postmenopausal women.

Conclusions: Our findings suggest for the first time that T and possibly E2 may be involved in the etiology of ICC.

Impact: The responsiveness of cervical tumors to hormone modulators is worth exploring.

Cancer Epidemiol Biomarkers Prev; 20(12); 2532–40. © 2011 AACR.
Introduction

Persistent infections with oncogenic human papilloma-virus (HPV) types are the necessary cause of invasive cervical carcinoma (ICC) and its precursor lesion (cervical intraepithelial neoplasia grade 3, CIN3; ref. 1). However, sex steroid hormones are essential for the differentiation and maturation of the human cervix and its vulnerability to HPV infection (2). The cervical epithelium remains relatively quiescent until the surge of estrogens and progesterone at puberty when the basal cells of the originally thin columnar epithelium transform into squamous cells in a physiologic process termed squamous metaplasia. This transformation area, called the squamous–columnar junction, is the preferential location of ICC. Eversion of the squamous–columnar lesion occurs during pregnancy and oral contraceptive use, facilitating direct exposure to and growth of HPV. Epidemiologic studies have shown that multiparity (3), recent oral contraceptive (OC) use (4), and, for not completely clear reasons, smoking (5) increase the risk of progression from cervical HPV infection to ICC. In addition, ICC incidence rates in unscreened populations stop increasing at around age 45 years (6), when sex steroid hormone levels start declining and the squamous–columnar junction withdrawing into the endocervix (7). A similar slowing in the increase of incidence rates in the perimenopausal period has also been observed for cancer of the breast (in unscreened populations), endometrium, and ovary whose development is clearly influenced by sex steroids (8). Although new cervical HPV infections continue to occur after middle age, the risk of CIN3 is decreased compared with younger women (9). These epidemiologic findings implicate sex steroid hormone levels in the development of ICC and CIN3. In vivo and in vitro laboratory studies also suggest that sex steroid hormones, especially estrogens, are required for the onset of atypical metaplasia in the squamous–columnar junction and ICC (10, 11).

To date, the association between serum or plasma levels of sex steroid hormones and the risk of ICC or CIN2 or 3 has been only evaluated in 3 case–control studies yielding inconsistent results (12, 13, 14). The aim of the present study was to assess the relationship between prediagnostic levels of sex steroid hormones and the risk of ICC and CIN3 in women enrolled in a prospective study, the European Prospective Investigation into Cancer and Nutrition (EPIC).

Materials and Methods

Study population and blood sample collection

The EPIC cohort included about 370,000 women, mainly aged 35 to 69 years, recruited between 1992 and 1998 in 23 centers in 10 European countries (Denmark, France, Germany, Greece, Italy, Norway, Spain, Sweden, the Netherlands, and the United Kingdom). Details on the cohort population and data collection procedures have been described elsewhere (15). In brief, extensive standardized questionnaire data were collected on habitual diet and lifestyle variables, including questions about reproductive and menstrual histories, current and past use of OCs and menopausal replacement therapy. Height, weight, and waist and hip circumferences were measured for most women while they were visiting the enrollment centers. However, anthropometric variables were self-reported in Norway and parts of the French and United Kingdom cohorts.

Blood samples were collected from about 65% of women in EPIC. In France, Germany, Greece, Italy, Norway, Spain, the Netherlands and the United Kingdom, blood was collected according to a standardized protocol: 30 mL of blood was withdrawn from each participant (16, 17). After centrifugation, samples were aliquotted into 0.5 mL straws of serum, plasma, red blood cells and buffy coat, and stored in liquid nitrogen containers (−196°C). A mirror half of these aliquots was stored locally in each of the centers whereas the other half was sent to the central bio-bank at the International Agency for Research on Cancer (IARC). In Denmark and Sweden, samples were stored only locally. In Denmark, samples were taken and aliquotted into 1 mL tubes, which were then stored in liquid nitrogen vapors (−150°C). In Sweden, samples were taken and stored into 1 mL aliquots in freezers at −80°C. The stability of steroid hormones and SHBG measurements on samples stored over long time periods at −80°C or lower temperature has been documented (18).

Follow-up for cancer incidence and vital status

Follow-up for vital status was collected through record linkage with regional/national cancer registries in all countries with the exception of France, Germany, and Greece, where these data were collected through an active follow-up. Incident ICC cases were identified through record linkage with regional cancer registries in Denmark, Norway, Spain, Sweden, the Netherlands, the United Kingdom, and in most of the Italian centers (complete to December 2005). In France, Germany, Greece, and Naples (Italy), follow-up (complete to December 2006) was based on a combination of methods, including health insurance records, cancer and pathology registries, and active follow-up through study subjects and their next-of-kin. For each EPIC study center, closure dates of the study period were defined as the latest dates of complete follow-up for both cancer incidence and vital status. Contrary to ICC cases, CIN3 cases were not systematically collected and consistently reported by all cancer registries and centers in EPIC and are, therefore, substantially fewer than expected (9).

Determination of menopausal status and phase of the menstrual cycle at blood donation

Women were considered as postmenopausal if they had reported at enrollment: (i) no menses over the past 12 months; (ii) bilateral ovariectomy; or (iii) age older than 55 years. Women were considered as premenopausal if they had reported: (i) regular menses over the past 12 months;
or (ii) age less than 42 years. Women between 42 and 55 years who reported hysterectomy without ovariectomy or for whom information on menopausal status was not available were classified as unknown menopausal status and excluded from the present study (16, 17).

In premenopausal women, the phase of the menstrual cycle at blood donation was determined as previously reported (16, 17). In brief, 2 different methods were used: “forward dating” counted forward from the woman’s reported start date of her last menses (information collected from the baseline questionnaires), and “backward dating” counted backward from the start date of her next menses after blood donation (information obtained from prepaid postcard that the woman sent back after her blood collection). When both types of information were available (Italy, Spain, and Oxford, United Kingdom), backward dating was used as the length of the second half of the cycle is generally more constant than that of the first half. The phase of a woman’s menstrual cycle was defined as: follicular (days 0–11 of the cycle), periovulatory (days 12–16), and luteal (from day 17 to the subsequent menstrual period).

**Nested case–control design and participation**

Cases were defined as women who had donated blood and developed ICC or CIN3 after enrollment into the EPIC study and before the end of the follow-up. Ineligibility criteria for the present study included: (i) use of OCs or menopausal replacement therapy at the time of blood donation (247 cases); (ii) history of cancer other than nonmelanoma skin cancer (11 cases); (iii) unknown menopausal status, or, among premenopausal women, unknown menstrual phase (71 cases). Twenty cervical neoplasias of uncertain malignant potential were also excluded.

Ninety-nine ICC cases and 121 CIN3 cases were included in the present analyses (Table 1). The distribution of ICC/CIN3 by country was as follows: 9/0 in Denmark; 0/2 in France; 13/4 in Greece; 13/22 in Germany; 11/10 in Italy; 11/3 in the Netherlands; 5/7 in Norway; 18/17 in Spain; 10/24 in Sweden; and 9/32 in the United Kingdom.

For each case of ICC or CIN3, 2 matched control women were chosen at random among appropriate risk sets consisting of all cancer-free cohort women who had reported no history of hysterectomy or bilateral ovariectomy at enrollment. An incidence density sampling procedure was used, that is, controls could be sampled more than once and may include women who became cases at a later time. Matching criteria were: center of enrollment; age (±6 months); time of the day and fasting status (<3 hours; 3–6 hours; >6 hours) at blood collection; date of entry; duration of follow-up time; menopausal status (pre-, postmenopausal) and, among premenopausal women, phase of the menstrual cycle (follicular, periovulatory, or luteal). All participants gave their consent for a broad range of use of their blood samples and the study was approved by the Institutional Review Board of IARC and all participating centers.

**Table 1. Comparison of cases of invasive cervical cancer and CIN3 and their matched controls by selected characteristics and menopausal status**

|                          | ICC/CIN3 | Controls | ICC/CIN3 | Controls | ICC/CIN3 | Controls | ICC/CIN3 | Controls |
|--------------------------|----------|----------|----------|----------|----------|----------|----------|----------|
| Number                   | 46       | 90       | 53       | 100      | 71       | 140      | 50       | 100      |
| Age at blood collectiona | 43.1 (35.3–51.0) | 46.7 (35.7–51.4) | 38.0 (35.8–51.0) | 42.1 (38.3–51.5) | 38.0 (35.8–51.0) | 42.1 (38.3–51.5) | 28.0 (35.8–51.0) | 42.1 (38.3–51.5) |
| Completion of secondary school, % | 47 | 28 | 46 | 26 | 47 | 28 | 46 | 26 |
| BMIa                      | 25.5 (20.9–32.4) | 25.3 (19.3–33.3) | 26.8 (19.8–36.5) | 26.8 (19.8–36.5) | 27.1 (19.7–38.5) | 27.1 (19.7–38.5) | 27.1 (19.7–38.5) | 27.1 (19.7–38.5) |
| Ever smokers, %           | 28.5 (13.0–37.5) | 28.5 (13.0–37.5) | 28.5 (13.0–37.5) | 28.5 (13.0–37.5) | 28.5 (13.0–37.5) | 28.5 (13.0–37.5) | 28.5 (13.0–37.5) | 28.5 (13.0–37.5) |

aMedian and 5th to 95th percentiles.
Laboratory assays

Sera were used for laboratory assays except in Norway (citrated plasma) and Sweden (EDTA and heparin plasma). Sex hormones can be accurately measured in serum as well as in plasma samples (19).

Total testosterone (T), dehydroepiandrosterone sulfate (DHEAS), and progesterone (premenopausal women only) levels were measured using a radioimmunoassay from Beckmann Coulter. Total estradiol (E₂) levels were measured by a radioimmunoassay from DiaSorin. Concentrations of sex hormone binding globulin (SHBG) were measured by a solid phase “sandwich” immunoradiometric assay (Cis-Bio International). Validation of the measurements of T and E₂ was previously reported (20). Free estradiol (fE₂) and free T (fT), that is, the fraction of these hormones that was not bound to either albumin or SHBG, were calculated from the total concentrations of T and E₂ by using mass action equations, assuming a constant concentration of albumin of 43 g/L. Validity of these equations in pre- and postmenopausal women was previously reported (21). Because of insufficient sample volume, DHEAS, E₂, and progesterone could not be measured in samples from Denmark.

All assays were carried out at IARC, without knowing case-control status. Samples belonging to matched case-control sets were always tested in the same batch. On the basis of results obtained for quality-control samples (containing low, medium, and high hormone concentrations, all measured in each of the analytical batches), the intra- and interbatch coefficients of variation were estimated. Intra- and interbatch coefficients of variation were 8.5% for T at a concentration of 2.7 nmol/L; 8.8% for DHEAS at 4.0 μmol/L; 2.3% for E₂ at 220 pmol/L; 4.4% for progesterone at 30.4 nmol/L; and 7.2% for SHBG at 40.0 nmol/L.

Statistical analyses

All statistical analyses were carried out separately for ICC and CIN3 and by menopausal status. Partial Spearman’s correlation coefficients between hormones and BMI between 39.1 years in premenopausal CIN3 cases to 58.0 for postmenopausal ICC cases. The mean interval between blood collection and tumor diagnosis ranged from 3.2 years for postmenopausal CIN3 cases to 4.2 years for postmenopausal ICC cases. ICC cases were significantly more often current or former smokers (Table 1) and past OC users (data not shown) than their matched control women. CIN3 cases were significantly leaner and more often current or former smokers than their matched control women.

Table 2 shows Spearman’s correlation coefficients between levels of sex steroid hormones and SHBG and BMI among control women, separately by menopausal status and adjusted for age and batch. In both pre- and postmenopausal women, the strongest positive correlations were found between T and DHEAS (0.61 and 0.67, respectively) and the strongest negative correlations between SHBG and BMI (−0.38 and −0.47). In premenopausal women, SHBG was positively correlated with E₂ (0.28) and negatively correlated with DHEAS (−0.36). In postmenopausal women, E₂ was positively correlated with T (0.42), DHEAS (0.21), and BMI (0.28) but inversely correlated with SHBG (−0.22). Smoking was positively correlated with SHBG (0.25) and negatively correlated with BMI (−0.24). Progesterone level in premenopausal women in the luteal phase was positively associated with...
SHBG (0.27) and \(E_2\) (0.29). All other correlations were 0.20 or lower (Table 2).

Table 3 shows ORs for ICC by level of total and free sex steroid hormones and SHBG, separately by menopausal status. Among premenopausal women, \(fT\) level was significantly associated with ICC risk (OR for the highest vs. lowest tertile \(= 5.16, \, 95\% \, CI, \, 1.50–20.1\)). A statistically significant inverse trend was observed for SHBG level,

| Table 2. Partial Spearman’s correlation coefficients between levels of sex steroid hormones and SHBG and BMI by menopausal status* among control women, adjusted for age and batch |
|-----------------|-------------|-------------|-------------|-------------|-------------|-------------|
| Testosterone    | DHEAS       | SHBG        | Estradiol\(^b\) | BMI         | Smoking\(^c\) | Progesterone\(^b\) |
| Testosterone    | 0.67        | 0.03        | 0.12         | 0.18        | -0.04        | 0.15         |
| DHEAS           | -0.16       | 0.36        | 0.28         | -0.38       | 0.27         |
| SHBG            | -0.36       | 0.10        | 0.28         | -0.38       | 0.27         |
| Estradiol\(^b\)| 0.03        | 0.11        | 0.22         | 0.06        | 0.03         |
| BMI             | 0.47        | 0.28        | -0.07        | -0.24       | -0.01        |
| Smoking         | 0.23        | 0.23        | -0.07        | -0.24       | -0.01        |

*Premenopausal women in italics and postmenopausal women bold faced.

Table 3. ORs and corresponding 95% CIs for invasive cervical cancer by tertile of circulating sex steroid hormone and SHGB levels and menopausal status

|                         | Premenopausal women |                         | Postmenopausal women |                         |
|-------------------------|---------------------|-------------------------|-----------------------|-------------------------|
|                         | Case:control\(^a\) OR (95% CI)\(^b\) | \(P_{trend}\) | Case:control\(^a\) OR (95% CI)\(^b\) | \(P_{trend}\) |
| Testosterone, nmol/L    |                      |                        |                       |                        |
| <1.11                   | 19:39               | ref.                   | <0.80                 | 11:32                   | ref.                   |
| 1.11–1.67               | 13:29               | 0.99 (0.40–2.37)       | 0.80–1.21             | 16:33                   | 1.59 (0.60–4.44)       |
| >1.67                   | 14:20               | 1.57 (0.56–4.48)       | 0.43–1.21             | 25:33                   | 3.14 (1.21–9.37)       |
| Free testosterone, pmol/L | <11.16               | 11:40                   | ref.                   | <9.35                   | 15:31                   | ref.                   |
| 11.16–19.99             | 19:29               | 2.66 (1.08–7.19)       | 9.35–15.73            | 17:36                   | 1.52 (0.58–4.04)       |
| >19.99                  | 15:17               | 5.16 (1.50–20.1)       | 0.005                 | 15:73                   | 20:31                   | 2.08 (0.81–5.64)       |
| DHEAS, \(\mu\)mol/L    | <3.27                | 14:34                   | ref.                   | <2.11                   | 14:34                   | ref.                   |
| 3.27–4.93               | 11:25               | 1.12 (0.41–3.10)       | 2.11–3.28             | 15:27                   | 1.72 (0.64–4.73)       |
| >4.93                   | 15:19               | 2.37 (0.84–7.36)       | 0.10–3.38             | 12:21                   | 1.72 (0.57–2.52)       |
| Estradiol, pmol/L       | <0.78\(^b\)         | 11:30                   | ref.                   | <30.79                  | 11:26                   | ref.                   |
| 0.78–1.23               | 17:23               | 3.23 (1.06–11.1)       | 30.79–39.32           | 11:31                   | 1.23 (0.41–3.81)       |
| >1.23                   | 17:37               | 1.50 (0.60–4.09)       | 0.48–9.32             | 20:27                   | 2.91 (0.90–10.7)       |
| Free estradiol, pmol/L  | <0.78\(^b\)         | 11:30                   | ref.                   | <0.66                   | 13:27                   | ref.                   |
| 0.78–1.24               | 15:23               | 2.27 (0.78–7.09)       | 0.66–9.32             | 16:30                   | 1.26 (0.49–3.30)       |
| >1.24                   | 18:36               | 1.71 (0.67–4.54)       | 0.29–9.96             | 13:30                   | 1.26 (0.40–4.11)       |
| Progesterone, nmol/L    | <0.76\(^b\)         | 6:13                    | ref.                   | —                      | —                      |
| 0.76–1.30               | 9:9                  | 3.50 (0.57–3.41)       | —                      | —                      |
| >1.30                   | 4:12                 | 0.46 (0.04–3.58)       | 0.51–5.51             | —                      |
| SHBG, nmol/L            | <59.26               | 21:23                   | ref.                   | <41.84                  | 12:33                   | ref.                   |
| 59.26–88.62             | 12:34               | 0.30 (0.09–0.86)       | 41.84–69.80           | 19:33                   | 1.29 (0.63–3.20)       |
| >88.62                  | 12:31               | 0.35 (0.11–1.04)       | 0.04–9.80             | 22:34                   | 1.22 (0.46–3.36)       |

\(^a\)Some figures do not add up to the total because of missing variables.

\(^b\)From conditional logistic regression analysis, conditioned on center, age, date, and time of day at blood collection, fasting status and, in premenopausal women, on phase of menstrual cycle (follicular, ovulatory or luteal); additional adjustments for BMI and smoking status.

\(^c\)Residuals from locally weighted regression models were used in premenopausal women; restricted to women in the luteal phase for progesterone. Residuals are not expressed in pmol/L as they are dimensionless.
with both medium (OR = 0.30, 95% CI, 0.09–0.86) and high (OR = 0.35, 95% CI, 0.11–1.04) levels associated with lower ICC risk. Positive associations were also observed for E₂, fE₂, and DHEAS levels but there was no statistically significant trend. No significant relationship was found between ICC risk and progesterone level in premenopausal women who gave blood in the luteal phase. Among postmenopausal women, positive associations with ICC were found with T (OR = 3.14; 95% CI, 1.21–9.37 for highest vs. lowest tertile; Table 3). Positive associations were also observed for fT and E₂ but there was no statistically significant trend. SHBG concentration was unrelated to ICC risk in postmenopausal women.

No substantial heterogeneity in the association between hormone or SHBG levels and ICC risk was observed by time interval between blood donation and ICC diagnosis (<3 vs. ≥3 years; results not shown).

Table 4 shows the relationship between levels of sex steroid hormones and SHBG and CIN3 risk, separately by menopausal status. No statistically significant associations were observed in either pre- or postmenopausal women.

Discussion

In the present prospective study, the first to date on the relationship between prediagnostic circulating levels of sex steroid hormones and ICC risk, we found a significant positive association with T or fT level in both pre- and postmenopausal women. On account of the different

Table 4. ORs and corresponding 95% CIs for CIN3 by tertile of circulating sex steroid hormone and SHBG level and menopausal status

|                  | Case:controla OR (95% CI)b | P_trend | Case:controla OR (95% CI)b | P_trend |
|------------------|-----------------------------|---------|-----------------------------|---------|
| **Premenopausal women** |                             |         |                             |         |
| Testosterone, nmol/L | <1.11                       | 17:37   | <0.80                       | 13:33   |
| 1.11–1.67         | 19:46                       | 0.87 (0.36–2.09) | 0.80–1.21 | 18:31   | 1.51 (0.59–4.09) |
| >1.67             | 35:55                       | 1.41 (0.55–3.67) | 0.44     | >1.21   | 1.21 (0.64–2.43) |
| Free testosterone, pmol/L | <11.16                      | 18:33   | ref.                        |         |
| 11.16–19.99       | 25:43                       | 0.91 (0.40–2.02) | 9.35–15.73 | 15:28   | 1.12 (0.42–2.99) |
| >19.99            | 25:55                       | 1.02 (0.44–2.48) | 0.96     | >15.73  | 1.16 (0.41–3.48) |
| DHEAS, μmol/L     | <3.27                       | 16:34   | ref.                        |         |
| 3.27–4.93         | 19:42                       | 0.88 (0.38–2.07) | 2.11–3.28 | 10:34   | 0.39 (0.13–1.11) |
| >4.93             | 28:48                       | 1.44 (0.60–3.65) | 0.38     | >3.28   | 22:39 | 0.71 (0.25–1.96) |
| Estradiol, pmol/L | <0.78c                      | 19:47   | ref.                        |         |
| 0.78–1.23         | 25:53                       | 1.00 (0.43–2.41) | 30.79–39.32 | 8:28   | 0.54 (0.18–1.49) |
| >1.23             | 26:40                       | 1.60 (0.64–4.18) | 0.31     | >39.32  | 20:32 | 1.40 (0.55–3.63) |
| Free estradiol, pmol/L | <0.78c                      | 21:46   | ref.                        |         |
| 0.78–1.24         | 27:52                       | 1.10 (0.52–2.36) | 0.66–0.96 | 9:32   | 0.51 (0.17–1.37) |
| >1.24             | 20:39                       | 0.94 (0.40–2.23) | 0.93     | >0.96   | 17:29 | 1.12 (0.41–3.03) |
| Progesterone, nmol/L | <0.76c                      | 4:11    | ref.                        |         |
| 0.76–1.30         | 9:15                        | 1.30 (0.32–6.01) | 11:34   | 11:34   | 1.16 (0.45–3.10) |
| >1.30             | 7:12                        | 0.99 (0.13–7.78) | 0.93     |         |         |
| SHBG, nmol/L      | <59.26                      | 19:51   | ref.                        |         |
| 59.26–88.62       | 25:39                       | 1.43 (0.59–3.50) | 41.84–69.80 | 18:34   | 1.16 (0.45–3.10) |
| >88.62            | 24:42                       | 1.05 (0.42–2.64) | 0.97     | >69.80  | 21:32 | 1.38 (0.52–3.89) |

aSome figures do not add up to the total because of missing variables.
bFrom conditional logistic regression analysis, conditioned on center, age, date, and time of day at blood collection, fasting status and, in premenopausal women, on phase of menstrual cycle (follicular, ovulatory, or luteal); additional adjustments for BMI and smoking status.
cResiduals from locally weighted regression models were used in premenopausal women; restricted to women in the luteal phase for progesterone. Residuals are not expressed in pmol/L as they are dimensionless.
behavior of SHBG level (inversely associated with ICC risk in pre- but not in postmenopausal women), fT level seemed to be a somewhat stronger predictor of ICC risk than total T in premenopausal women but not in postmenopausal women. Positive associations between ICC risk and DHEAS, E₂, and fE₂ level were also observed but there was no significant trend. We assessed progesterone levels only in premenopausal women who had their blood collected in the luteal phase, and found progesterone unrelated to ICC risk although the corresponding OR had a very broad CI. No associations were found between sex steroid hormone or SHBG levels and CIN3 risk in either pre- or postmenopausal women although, again, the CI of the corresponding ORs do not allow us to rule out associations in either direction.

The relationship between circulating sex steroid hormones and the risk of cancerous or precancerous cervical lesions has been previously investigated in 3 case–control studies (12, 13, 14). Zheng included 51 postmenopausal women with ICC and 52 cancer-free postmenopausal women (12). ICC cases had statistically significant higher serum levels of estrone and estriol than control women whereas no differences were reported for E₂. Wang and colleagues compared 141 ICC cases with 2 control groups (137 women with uterine myoma and 129 healthy women; ref. 13). Serum E₂ levels were significantly higher among ICC cases than in either control group whereas progesterone level did not differ. Shields and colleagues compared cross-sectionally plasma E₂, estrone, SHBG, DHEAS, and progesterone levels in 110 women with CIN2, 3, or ICC to 440 women with normal cytology or CIN1 selected within the Guanacaste cohort study, Costa Rica (14). Half of the control women were chosen among HPV-positive women. No significant associations were found between the risk of CIN2 or worse lesions and levels of sex steroid hormones or SHBG.

The partial disagreement between our findings and those of Shields and colleagues (14) may be explained by the fact that cases in their study mainly included CIN2 and CIN3 (85 of 110), whereas the association we found with T and fT and, possibly, E₂ levels were observed but there was no significant trend. We assessed progesterone levels only in premenopausal women who had their blood collected in the luteal phase, and found progesterone unrelated to ICC risk although the corresponding OR had a very broad CI. No associations were found between sex steroid hormone or SHBG levels and CIN3 risk in either pre- or postmenopausal women although, again, the CI of the corresponding ORs do not allow us to rule out associations in either direction.

The present study has strengths and weaknesses. It derives from a large cohort study but it includes relatively few ICC and CIN3 cases due, respectively, to the low incidence of ICC among the European women who voluntarily joined the EPIC study, and severely incomplete follow-up for CIN3. In addition, a substantial number of women had to be excluded, notably because their menopausal status or menstrual cycle phase were ill-defined with respect to ICC, and their evaluation is severely confounded by intense screening in menopausal replacement therapy users (34).

The conclusion on whether androgens, estrogens or both may be involved in cervical carcinogenesis is difficult because the 2 hormones are biochemically closely related. Long-term T level can be inferred from one-time measurement much more reliably than E₂ level (16, 17, 24). However, the 2 hormones are biochemically closely related. Long-term T level can be inferred from one-time measurement much more reliably than E₂ level (16, 17, 24). Contrary to T (25), E₂ level in premenopausal women varies enormously throughout the menstrual cycle, making a single measurement insufficient to classify long-term exposure accurately (7). In postmenopausal women, the comparison of the effect of T and E₂ is complicated by the fact that T is the main source of E₂ after ovarian estrogen production has stopped and T levels are much higher than E₂ levels (24).

A negative association between ICC risk and SHBG level in premenopausal but not in postmenopausal women had never been reported before. Conversely, negative associations with SHBG levels have been consistently reported with postmenopausal breast cancer risk (24). Low SHBG level implies higher bioavailability of estrogens and may indicate higher levels of insulin or insulin-like growth factor-1 (26). A direct inhibitory role of SHBG on breast cancer cell proliferation has also been proposed (27).

In transgenic mice that express HPV16 E6 and E7 oncogenes, estrogen is required for the onset of ICC (10, 11). Estrogens have a profound influence on the cervical squamous–columnar junction from which ICC arises in mice and in humans (28), and the estrogen receptor α has been shown to be necessary for cervical cancer to arise in mice (11). Drugs that interfere with the function of estrogen receptor α (e.g., raloxifene) have been shown to prevent the onset or induce the regression of ICC in transgenic mice (11) but corresponding data in humans are scant (29).

Epidemiologic data on the association of full-term pregnancies and recent OC use with ICC risk, and the cessation of the increase in ICC incidence rates after menopause also suggest an involvement of high estrogen levels but do not allow to rule out an influence of progesterone or androgens (30). The 2 best correlates of high unopposed estrogen levels in postmenopausal women (i.e., overweight/obesity (31) and the use of estrogen-only menopausal replacement therapy (32, 33) have been little studied in respect to ICC, and their evaluation is severely confounded by intense screening in menopausal replacement therapy users (34).

The conclusion on whether androgens, estrogens or both may be involved in cervical carcinogenesis is difficult because the 2 hormones are biochemically closely related. Long-term T level can be inferred from one-time measurement much more reliably than E₂ level (16, 17, 24). Contrary to T (25), E₂ level in premenopausal women varies enormously throughout the menstrual cycle, making a single measurement insufficient to classify long-term exposure accurately (7). In postmenopausal women, the comparison of the effect of T and E₂ is complicated by the fact that T is the main source of E₂ after ovarian estrogen production has stopped and T levels are much higher than E₂ levels (24).
disease (4, 5). Lack of adjustment for HPV infection is not of great concern as all ICC cases can be assumed to harbor a long-duration infection (1). Conversely, HPV positivity at one point in time among control women is difficult to interpret as it may be either a recent or long-duration infection (4). All hormonal analyses were adjusted for BMI and smoking status as these factors can modify levels of sex steroid hormones and SHBG. Indeed, hormonal modifications may be one of the mechanisms through which BMI and smoking affect ICC risk. Finally, null findings for CIN3 should be interpreted very cautiously.

Notwithstanding these limitations, our present findings are a strong reminder that, despite the unique role of HPV infection in cervical cancer (1), the cervix epithelium is a hormone-dependent epithelium (35). Although the hormonal balance responsible for risk increase varies by cancer site, sex steroid hormones are likely to be implicated in ICC etiology as it has been more convincingly shown for cancer of the breast (24, 36), endometrium, and ovary (8).

Biobanks from existing prospective studies should be used to confirm our present limited data on the influence of sex hormone levels on cancers and precancerous cervical lesions and new mechanistic studies on the effect of estrogens, progesterone, and androgens on HPV-infected cervical cells should be started (30). ICC can be effectively prevented through screening and HPV vaccination programs, and treated with surgery and radiotherapy (37). Elucidating the dependence of cervical lesions on sex steroid hormones (29, 30) may allow, however, the discovery of hormone modulators that could further improve ICC control by, for example, decreasing recurrences of cancerous and precancerous lesions.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
The Authors thank David Achiandine and Thomas Cler for the valuable and meticulous work in conducting laboratory analyses, Bertrand Hemon for the precious help with database preparation, and Veronique Chabanis for editorial assistance.

Grant Support
The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM; France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); Hellenic Health Foundation, Starrs Niarchos Foundation and Hellenic Ministry of Health and Social Solidarity (Greece); Italian Association for Research on Cancer (AIRC) and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKI), LR Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (the Netherlands); ERC-2009-AdG:232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), Regional Governments of Andalucia, Asturias, Basque Country, Murcia (project no. 6286) and Navarra, ISCHII RETIC (RD06/0120; Spain); Swedish Cancer Society, Swedish Scientific Council and Regional Government of Skane and Vasterbotten (Sweden); Cancer Research United Kingdom, Medical Research Council, Stroke Association, British Heart Foundation, Department of Health, Food Standards Agency, and Wellcome Trust (United Kingdom). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 8, 2011; revised September 16, 2011; accepted October 3, 2011; published OnlineFirst October 12, 2011.

References
1. IARC Monographs on the evaluation of carcinogenic risks to humans. Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. Vol 91. Lyon, France: IARC Press; 2008.
2. Hwang LY, Ma Y, Benningfield SM, Clayton L, Hanson EN, Jay J, et al. Factors that influence the rate of epithelial maturation in the cervix in healthy young women. J Adolesc Health 2009;44:103–10.
3. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,573 women with cervical cancer and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 2006;118:1108–24.
4. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data on 16,573 women with cervical cancer and 35,508 women without cervical cancer from 24 epidemiological studies. Lancet 2007;370:1609–21.
5. International Collaboration of Epidemiological Studies of Cervical Cancer. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006;118:1481–95.
6. Plummer M, Petro J, Franceschi S. Time since first sexual intercourse and the risk of cervical cancer. Int J Cancer 2011 Aug 12. [Epub ahead of print].
7. Burger H. The menopausal transition–endocrinology. J Sex Med 2008;5:2266–73.
8. Pike MC, Pearce CL, Wu AH. Prevention of cancers of the breast, endometrium and ovary. Oncogene 2004;23:6379–91.
9. Rodriguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010;102:315–24.
10. Brake T, Lambert PF. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci U S A 2005;102:2490–5.
11. Chung SH, Lambert PF. Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists. Proc Natl Acad Sci U S A 2009;106:19467–72.
12. Zheng Y. [Plasma estrogen level in patients with cervical cancer]. Zhonghua Liu Za Zhi 1990;12:404–5.
13. Wang JT, Gao ES, Ding L, Cheng YY, Yan JW. [Association between endogenous hormones, hormone receptors and cervical cancer]. Zhonghua Zhong Liu Za Zhi 2006;28:494–7.
14. Shields TS, Falk RT, Herrero R, Schiffman M, Weiss NS, Bratti C, et al. A case-control study of endogenous hormones and cervical cancer. Br J Cancer 2004;90:146–52.
15. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study...
populations and data collection. Public Health Nutr 2002;5:1113–24.
16. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Bressy C, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005;97:755–65.
17. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Bressy C, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 2005;12:1071–82.
18. Garcia-Closas M, Hankinson SE, Ho S, Malins DC, Polissar NL, Schaefer SN, et al. Factors critical to the design and execution of epidemiologic studies and description of an innovative technology to follow the progression from normal to cancer tissue. J Natl Cancer Inst Monogr 2000;27:147–56.
19. Bolelli G, Muti P, Micheli A, Scianjo R, Franceschetti F, Krogh V, et al. Validity for epidemiological studies of long-term cryoconservation of steroid and protein hormones in serum and plasma. Cancer Epidemiol Biomarkers Prev 1995;4:509–13.
20. Rinaldi S, Dechaud H, Bressy C, Morin-Raverot V, Toniolo P, Zele
niuch-Jacquotte A, et al. Reliability and validity of commercially available, direct radioimmunoassays for measurement of blood androgens and estrogens in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10:757–65.
21. Rinaldi S, Geay A, Dechaud H, Bressy C, Zeleniuch-Jacquotte A, Akhmedkhanov A, et al. Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev 2002;11:1065–71.
22. Willett WC, Howe GR, Kushi LH. Adjustment for total energy intake in epidemiologic studies. Am J Clin Nutr 1997;65 4 Suppl:1220S–8S.
23. Gelman A, Jakulin A, Pittau MG, Su YS. A weakly informative default prior distribution for logistic and other regression models. Ann Appl Stat 2008;2:1360–83.
24. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:806–16.
25. Davison SL, Bell R. Androgen physiology. Semin Reprod Med 2006; 24:71–7.
26. Lipworth L, Adam HI, Trichopoulos D, Carlstrom K, Mantzoros C. Serum steroid hormone levels, sex hormone-binding globulin, and body mass index in the etiology of postmenopausal breast cancer. Epidemiology 1996;7:96–100.
27. Fortunati N, Catalano MG, Bocuzzi G, Fraria R, Sex hormone-binding globulin (SHBG), estradiol and breast cancer. Mol Cell Endocrinol 2010;316:86–92.
28. Elston DA, Riley RR, Lacey A, Thorarinson G, Talamantes FJ, Arbeit JM. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res 2000;60:1267–75.
29. Castle PE. Do selective estrogen receptor modulators treat cervical precancer and cancer? Time to pool data from relevant trials. Int J Cancer 2011;128:997–8.
30. Chung SH, Franceschi S, Lambert PF. Estrogen and ERalphas: culprits in cervical cancer? Trends Endocrinol Metab 2010;21:504–11.
31. Lacey JV Jr, Swanson CA, Brinton LA, Altekruse SF, Barnes WA, Gravitt PE, et al. Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer 2003;98:814–21.
32. Parazzini F, Chatenoud L, La Vecchia C, Chiaffarino F, Ricci E, Negri E. Time since last use of oral contraceptives and risk of invasive cervical cancer. Eur J Cancer 1998;34:884–8.
33. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pet
tinger M, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA 2003;290:1739–48.
34. Franceschi S, Plummer M, Clifford G, de Sanjos/E19, Bosch X, Herrero R, et al. Differences in the risk of cervical cancer and human pap
ilomavirus infection by education level. Br J Cancer 2008;101: 865–70.
35. Allen E, Gardner W. Cancer of the cervix of the uterus in hybrid mice following long-continued administration of estrogen. Cancer Res 1941;1:359–66.
36. Santen RJ, Boyd NF, Chlebowski RT, Cummings S, Cuzick J, Dowsett M, et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer 2007;14:169–87.
37. Trimble CL, Frazer IH. Development of therapeutic HPV vaccines. Lancet Oncol 2009;10:975–80.
Endogenous Sex Steroids and Risk of Cervical Carcinoma: Results from the EPIC Study

Sabina Rinaldi, Martyn Plummer, Carine Biessy, et al.

Cancer Epidemiol Biomarkers Prev 2011;20:2532-2540. Published OnlineFirst October 12, 2011.

Updated version
Access the most recent version of this article at: doi:10.1158/1055-9965.EPI-11-0753

Cited articles
This article cites 35 articles, 10 of which you can access for free at: http://cebp.aacrjournals.org/content/20/12/2532.full#ref-list-1

Citing articles
This article has been cited by 3 HighWire-hosted articles. Access the articles at: http://cebp.aacrjournals.org/content/20/12/2532.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cebp.aacrjournals.org/content/20/12/2532. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.